The pharmacogenetics of coumarin therapy

Deepak Voora, Howard L. McLeod, Charles Eby, Brian F. Gage

Research output: Contribution to journalReview articlepeer-review

79 Scopus citations

Abstract

Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumarin dose response have been identified. A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation.

Original languageEnglish
Pages (from-to)503-513
Number of pages11
JournalPharmacogenomics
Volume6
Issue number5
DOIs
StatePublished - Jul 1 2005

Keywords

  • Acenocoumarol
  • CYP enzyme system
  • Genetic
  • Pharmacogenetics
  • Phenprocoumon
  • Polymorphism
  • Warfarin

Fingerprint Dive into the research topics of 'The pharmacogenetics of coumarin therapy'. Together they form a unique fingerprint.

Cite this